Key result
Losartan cuts tumour volume ~79% in experimental rat glioma with decreased vascular density and proliferation.
Why the study?
Angiotensin II mediates angiogenesis and growth factor transcription via the AT1 receptor, but the presence and therapeutic targeting of AT1R in glioma cells was unclear.
Does losartan reduce tumor growth and angiogenesis in a rat glioma model?
Does losartan reduce tumor growth and angiogenesis in a rat glioma model?
Blockade of the AT1 receptor with losartan significantly reduces tumor growth and angiogenesis in an experimental rat glioma model.
Hypothesis-generating in rat glioma; leaves open clinical translation of AT1 blockade pending human trials.
Malignancy of neoplasms is partly dependent on angiogenesis. Angiotensin II mediates angiogenesis and transcription of growth-related factors through stimulation of the AT1 receptor (AT1R). Losartan, a drug used mostly for treatment of hypertension, binds strongly to this receptor. We found the presence of AT1 receptor on C6 glioma cells and studied the effect of Losartan on the growth and angiogenesis of C6 rat glioma; Losartan in dose of 80 mg/kg induced 79% reduction of tumoural volume with a significant decrease of vascular density, mitotic index and cell proliferation. Our results demonstrate the conspicuous presence of AT1R in malignant glial cells and a favourable therapeutic response in experimental glioma by selective blockage of the AT1 receptor.
No takes yet. Share an insight, caveat, or question.
Rivera et al. (2001) studied C6 rat glioma. Losartan was evaluated on Tumoural volume, vascular density, mitotic index, and cell proliferation. Losartan at a dose of 80 mg/kg induced a 79% reduction in tumoural volume with a significant decrease in vascular density, mitotic index, and cell proliferation in experimental rat glioma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: